In the BioHarmony Drug Report Database

"Preview" Icon

Telotristat ethyl

Xermelo (telotristat ethyl) is a small molecule pharmaceutical. Telotristat ethyl was first approved as Xermelo on 2017-09-17. It is used to treat diarrhea and malignant carcinoid syndrome in the USA. It has been approved in Europe to treat carcinoid tumor and neuroendocrine tumors. It is known to target tryptophan 5-hydroxylase 1.

 

Trade Name

 

Xermelo
 

Common Name

 

telotristat ethyl
 

ChEMBL ID

 

CHEMBL2105695
 

Indication

 

carcinoid tumor, diarrhea, malignant carcinoid syndrome, neuroendocrine tumors
 

Drug Class

 

Enzyme inhibitors: tryptophan hydroxylase inhibitors

Image (chem structure or protein)

Telotristat ethyl structure rendering